Generex Biotechnology Corp Stock Price To Earning
| GNBTDelisted Stock | USD 0.0001 0.00 0.00% |
Generex Biotechnology Corp fundamentals help investors to digest information that contributes to Generex Biotechnology's financial success or failures. It also enables traders to predict the movement of Generex OTC Stock. The fundamental analysis module provides a way to measure Generex Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Generex Biotechnology otc stock.
Generex |
Generex Biotechnology Corp OTC Stock Price To Earning Analysis
Generex Biotechnology's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Generex Biotechnology Price To Earning | 5.59 X |
Most of Generex Biotechnology's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Generex Biotechnology Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Generex Biotechnology Corp has a Price To Earning of 5.59 times. This is 78.37% lower than that of the Biotechnology sector and 13.39% higher than that of the Health Care industry. The price to earning for all United States stocks is 80.54% higher than that of the company.
Generex Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Generex Biotechnology's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Generex Biotechnology could also be used in its relative valuation, which is a method of valuing Generex Biotechnology by comparing valuation metrics of similar companies.Generex Biotechnology is currently under evaluation in price to earning category among related companies.
Generex Fundamentals
| Return On Equity | -17.73 | |||
| Return On Asset | -0.44 | |||
| Operating Margin | (49.52) % | |||
| Current Valuation | 7.68 M | |||
| Shares Outstanding | 118.45 M | |||
| Shares Owned By Institutions | 0.02 % | |||
| Number Of Shares Shorted | 211.98 K | |||
| Price To Earning | 5.59 X | |||
| Price To Sales | 0.10 X | |||
| Revenue | 2.66 M | |||
| Gross Profit | 2.08 M | |||
| EBITDA | (26.12 M) | |||
| Net Income | (33.34 M) | |||
| Cash And Equivalents | 1.68 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 499.66 K | |||
| Current Ratio | 0.04 X | |||
| Book Value Per Share | (0.48) X | |||
| Cash Flow From Operations | (6.12 M) | |||
| Short Ratio | 1.73 X | |||
| Earnings Per Share | (0.37) X | |||
| Target Price | 6.0 | |||
| Number Of Employees | 15 | |||
| Beta | -0.0623 | |||
| Market Capitalization | 71.07 K | |||
| Total Asset | 45.38 M | |||
| Retained Earnings | (373.34 M) | |||
| Working Capital | (8.68 M) | |||
| Current Asset | 55 K | |||
| Current Liabilities | 8.73 M | |||
| Z Score | -11.2 | |||
| Net Asset | 45.38 M |
About Generex Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Generex Biotechnology Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Generex Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Generex Biotechnology Corp based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Generex Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Generex Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Generex Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving against Generex OTC Stock
| 0.88 | MMM | 3M Company Financial Report 23rd of July 2024 | PairCorr |
| 0.85 | GE | GE Aerospace Financial Report 23rd of July 2024 | PairCorr |
| 0.82 | CVX | Chevron Corp Financial Report 26th of July 2024 | PairCorr |
| 0.82 | DD | Dupont De Nemours Earnings Call This Week | PairCorr |
| 0.73 | CAT | Caterpillar Financial Report 6th of August 2024 | PairCorr |
The ability to find closely correlated positions to Generex Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Generex Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Generex Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Generex Biotechnology Corp to buy it.
The correlation of Generex Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Generex Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Generex Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Generex Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Generex Biotechnology information on this page should be used as a complementary analysis to other Generex Biotechnology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Generex OTC Stock
If you are still planning to invest in Generex Biotechnology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Generex Biotechnology's history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |